

Signant SmartSignals® Solutions for Schizophrenia

CLINICAL DEVELOPMENT SOLUTIONS TO IMPROVE SCHIZOPHRENIA STUDY OUTCOMES

Schizophrenia is a leading cause of patient suffering and disability around the world. Despite the compelling, unmet need for new and more effective treatments, the development process remains challenging. Signant Health optimizes schizophrenia trials by applying unrivaled global experience and proven clinical research technologies, supported by indication-specific scientific expertise, to help study teams increase opportunities for success.

OPTIMIZE CLINICAL RATINGS RELIABILITY

Signant's scientific advisory and technology solutions pair together to ensure reliable endpoint data. For example, our site-independent assessment of eligibility criteria ensures appropriate patients are enrolled, while our Rater Training & Qualification solution ensures raters adhere to scoring and administration conventions of efficacy outcomes.

MONITOR ENDPOINT DATA IN REAL-TIME

By leveraging the most experience and largest data sets in Schizophrenia research, Signant's PureSignal Analytics improves the reliability of endpoint data. The solution combines proprietary algorithms and expertise of in-house clinicians to identify and mitigate risks to clinical outcome assessment data, in real-time, to optimize signal detection.

SIMPLIFY ASSESSMENTS & ADHERENCE FOR PARTICIPANTS

Patient-reported and clinician-reported outcome assessments are vital to fully evaluate schizophrenia treatment efficacy and impact. Our eCOA solution can be tailored to sites' and patient's needs – guided assessments and built-in edit checks reduce COA errors, while alerts and reminders help improve adherence to medication dosing schedules.

SIMPLIFY STUDY MEDICATION MANAGEMENT

Handle the medication management and patient randomization requirements in your protocol with ease. Our RTSM system and powerful algorithms handle complex dosing schedules, patient cohort schemes, and adaptive designs. Plus, our agile implementation model allows for rapid deployment including mid-study amendments.

MAXIMIZE SIGNAL DETECTION OPPORTUNITIES

Talk through your schizophrenia protocol with our science and medicine experts, who serve as an extension of your study team. We guide the selection and acquisition of endpoints and assessments, advise on inclusion/exclusion criteria, and recommend methods to decrease site and participant burdens. Our end goal is to optimize the reliability of your study's endpoint data.

At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for people living with schizophrenia.

SIGNANT'S SCHIZOPHRENIA EXPERIENCE BY THE NUMBERS



I - IV
PHASES



158
TRIALS



4.3k
SITES



15.5k
PATIENTS



60
COUNTRIES



23
LANGUAGES

DRIVE BETTER RESEARCH OUTCOMES WITH SIGNANT SMARTSIGNALS SOLUTIONS

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.



eCOA

[LEARN MORE →](#)



RTSM

[LEARN MORE →](#)



SCIENTIFIC
ADVISORY

[LEARN MORE →](#)



PURESIGNAL
ANALYTICS

[LEARN MORE →](#)



RATER TRAINING
& QUALIFICATION

[LEARN MORE →](#)

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)